New opportunities and old challenges in the clinical translation of nanotheranostics

Gawne, Peter J.; Ferreira, Miguel; Papaluca, Marisa; Grimm, Jan; Decuzzi, Paolo

doi:10.1038/s41578-023-00581-x

Cited by 29 publications

(11 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past few decades, the benefits of nanomedicine have attracted worldwide attention, creating a hotspot for research. Many nanomedicines have entered preclinical and clinical studies. − Moreover, some of them have been approved by the U.S. Food and Drug Administration (FDA) and entered the market, such as liposomal doxorubicin (Doxil) and nab-paclitaxel (Abraxane), which are the most successful and representative nanomedicines so far. − …”

Section: Fundamental Question Of Nanomedicinesmentioning

confidence: 99%

Nanomedomics

Liang,

Cao,

Tang

et al. 2024

ACS Nano

View full text Add to dashboard Cite

Nanomaterials have attractive physicochemical properties. A variety of nanomaterials such as inorganic, lipid, polymers, and protein nanoparticles have been widely developed for nanomedicine via chemical conjugation or physical encapsulation of bioactive molecules. Superior to traditional drugs, nanomedicines offer high biocompatibility, good water solubility, long blood circulation times, and tumor-targeting properties. Capitalizing on this, several nanoformulations have already been clinically approved and many others are currently being studied in clinical trials. Despite their undoubtful success, the molecular mechanism of action of the vast majority of nanomedicines remains poorly understood. To tackle this limitation, herein, this review critically discusses the strategy of applying multiomics analysis to study the mechanism of action of nanomedicines, named nanomedomics, including advantages, applications, and future directions. A comprehensive understanding of the molecular mechanism could provide valuable insight and therefore foster the development and clinical translation of nanomedicines.

show abstract

Section: Fundamental Question Of Nanomedicinesmentioning

confidence: 99%

Nanomedomics

Liang,

Cao,

Tang

et al. 2024

ACS Nano

View full text Add to dashboard Cite

show abstract

“…16 In addition, NCs can be equipped with imaging agents or sensors, allowing for real-time monitoring of drug distribution, release, and therapeutic effects. 17 This becomes particularly pertinent in the context of personalized medicine, where treatments should be tailored to an individual's unique disease characteristics and response to therapy. Yet, NCs' adaptability and inherent flexibility in composition, architecture, and therapeutic cargo contribute to their challenge in clinical translation.…”

Section: Vehicles For Personalized Medicinementioning

confidence: 99%

“…Their ability to carry potent therapeutic agents with poor solubility and high toxicity has long been recognized in the form of Doxil, the first clinically approved nanodrug . In addition, NCs can be equipped with imaging agents or sensors, allowing for real-time monitoring of drug distribution, release, and therapeutic effects . This becomes particularly pertinent in the context of personalized medicine, where treatments should be tailored to an individual’s unique disease characteristics and response to therapy.…”

Section: Nanocarriers As Precision Delivery Vehicles For Personalized...mentioning

confidence: 99%

“…Wilhelm et al compiled data from clinical studies revealing that only <1% of administered NC dose reached the intended targeted solid tumors . While the number of clinically available nanomedicines is increasing, they are still below the projections for the field as they face additional challenges compared to conventional drug development. ,,,, Since 2016, lipid-based and liposomal nanoparticles have been the most common in both clinical trials (Figure ) and FDA-approved drugs . In 2021, over 30 nanoparticles have been approved and used in clinical applications …”

Section: Nanocarriers As Precision Delivery Vehicles For Personalized...mentioning

confidence: 99%

See 1 more Smart Citation

Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems

Svensson,

von Mentzer,

Stubelius

2023

ACS Mater. Au

View full text Add to dashboard Cite

The ability to customize medical choices according to an individual’s genetic makeup and biomarker patterns marks a significant advancement toward overall improved healthcare for both individuals and society at large. By transitioning from the conventional one-size-fits-all approach to tailored treatments that can account for predispositions of different patient populations, nanomedicines can be customized to target the specific molecular underpinnings of a patient’s disease, thus mitigating the risk of collateral damage. However, for these systems to reach their full potential, our understanding of how nano-based therapeutics behave within the intricate human body is necessary. Effective drug administration to the targeted organ or pathological niche is dictated by properties such as nanocarrier (NC) size, shape, and targeting abilities, where understanding how NCs change their properties when they encounter biomolecules and phenomena such as shear stress in flow remains a major challenge. This Review specifically focuses on vessel-on-a-chip technology that can provide increased understanding of NC behavior in blood and summarizes the specialized environment of the joint to showcase advanced tissue models as approaches to address translational challenges. Compared to conventional cell studies or animal models, these advanced models can integrate patient material for full customization. Combining such models with nanomedicine can contribute to making personalized medicine achievable.

show abstract

“…Nowadays, immunogenic cell death (ICD) has proven to be a powerful tool for cancer treatment. − In general, throughout the ICD process, plenty of tumor-associated antigens (TAAs), such as calreticulin (CRT), adenosine triphosphate (ATP), and high mobility group box-1 (HMGB-1), are released. This release serves to induce the maturation of dendritic cells and infiltration of T-lymphocyte cells into the tumor region.…”

Section: Introductionmentioning

confidence: 99%

Polysarcosine as PEG Alternative for Enhanced Camptothecin-Induced Cancer Immunogenic Cell Death

Yao,

Sun,

Xiong

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Nanomedicine-enhanced immunogenic cell death (ICD) has attracted considerable attention for its great potential in cancer treatment. Even though polyethylene glycol (PEG) is widely recognized as the gold standard for surface modification of nanomedicines, some shortcomings associated with this PEGylation, such as hindered cell endocytosis and accelerated blood clearance phenomenon, have been revealed in recent years. Notably, polysarcosine (PSar) as a highly biocompatible polymer can be finely synthesized by mild ring-opening polymerization (ROP) of sarcosine N-carboxyanhydrides (Sar-NCAs) and exhibit great potential as an alternative to PEG. In this article, PSar-b-polycamptothecin block copolymers are synthesized by sequential ROP of camptothecin-based NCAs (CPT-NCAs) and Sar-NCAs. Then, the detailed and systematic comparison between PEGylation and PSarylation against the 4T1 tumor model indicates that PSar decoration can facilitate the cell endocytosis, greatly enhancing the ICD effects and antitumor efficacy. Therefore, it is believed that this well-developed PSarylation technique will achieve effective and precise cancer treatment in the near future.

show abstract

New opportunities and old challenges in the clinical translation of nanotheranostics

Cited by 29 publications

References 135 publications

Nanomedomics

Nanomedomics

Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems

Polysarcosine as PEG Alternative for Enhanced Camptothecin-Induced Cancer Immunogenic Cell Death

Contact Info

Product

Resources

About